In this episode, Ayesha talked about the breakthrough FDA approval of Provention Bio’s Tzield for delaying the onset of type 1 diabetes in adult and pediatric patients. It’s the first approved treatment for slowing the progression of stage 2 type 1 diabetes to stage 3, the stage at which a clinical diagnosis is made. Tzield is an immunotherapy that was in development for over three decades. Find out more about the drug and how it may be a gamechanger for type 1 diabetes.

Ayesha also talked about the latest positive Phase III trial data that Pfizer recently shared for its maternal RSV vaccine candidate. The data showed that the vaccine led to a significant reduction in the rate of severe medically attended lower respiratory tract illness (MA-LRTI) in newborns, a complication that can result from respiratory syncytial virus (RSV) infection. Hear more about the vaccine trial data, based on which an independent data monitoring committee has recommended that Pfizer file with the FDA for approval.

Read the full articles here:

Tzield Gets FDA Nod to Become First Approved Drug to Delay Onset of Type 1 Diabetes

Pfizer Shares Positive Phase III Data for Maternal RSV Vaccine Candidate

For more life science and medical device content, visit the Xtalks Vitals homepage.

Follow Us on Social Media

Twitter: @Xtalks